Carbapenem-resistant enterobacteriaceae: Epidemiology and prevention

Clinical Infectious Diseases

Volumn 53, Issue 1, 2011, Pages 60-67

  Gupta, Neil ^a,b   Limbago, Brandi M ^b   Patel, Jean B ^b   Kallen, Alexander J ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; CEPHALOSPORIN DERIVATIVE; COLISTIN; DORIPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; QUINOLONE DERIVATIVE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE; DEVICE INFECTION; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; HUMAN; INFECTION PREVENTION; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; MORTALITY; MULTIDRUG RESISTANCE; MULTILOCUS SEQUENCE TYPING; PRIORITY JOURNAL; PROTEUS; PROVIDENCIA; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; SEROEPIDEMIOLOGY; UNITED STATES;

BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS;

EID: 79958818528     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir202     Document Type: Review

References (48)

1. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352:380-91.
2. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: Antimicrobialresistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996-1011.
3. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenemresistant Klebsiella pneumoniae in New York City: A new threat to our antibiotic armamentarium. Arch Intern Med 2005; 165:1430-5. (Pubitemid 40973427)
4. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29:1099-106.
5. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008; 52:1028-33. (Pubitemid 351358384)
6. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991; 35:147-51.
7. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenemhydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45:1151-61. (Pubitemid 32230996)
8. Bratu S, Brooks S, Burney S, et al. Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis 2007; 44:972-5. (Pubitemid 46452064)
9. Gaynes RP, Culver DH. Resistance to imipenem among selected gram-negative bacilli in the United States. Infect Control Hosp Epidemiol 1992; 13:10-4.
10. Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection program: A 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009; 65:414-26.
11. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother 1997; 41:563-9. (Pubitemid 27098404)
12. Chow JW, Shlaes DM. Imipenem resistance associated with the loss of a 40 kDa outer membrane protein in Enterobacter aerogenes. J Antimicrob Chemother 1991; 28:499-504.
13. MacKenzie FM, Forbes KJ, Dorai-John T, Amyes SG, Gould IM. Emergence of a carbapenem-resistant Klebsiella pneumoniae. Lancet 1997; 350:783.
14. Queenan AM, Bush K. Carbapenemases: The versatile beta-lactamases. Clin Microbiol Rev 2007; 20:440-58.
15. Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenem- hydrolyzing beta-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother 2005; 49:4423-4. (Pubitemid 41401006)
16. Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007; 51:3026-9. (Pubitemid 47206254)
17. Navon-Venezia S, Leavitt A, Schwaber MJ, et al. First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother 2009; 53:818-20.
18. Kitchel B, Rasheed JK, Patel JB, et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: Clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009; 53:3365-70.
19. Castanheira M, Sader HS, Jones RN. Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae. Microb Drug Resist 2010; 16:61-5.
20. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: Risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009; 30:666-71.
21. Elemam A, Rahimian J, Mandell W. Infection with panresistant Klebsiella pneumoniae: A report of 2 cases and a brief review of the literature. Clin Infect Dis 2009; 49:271-4.
22. Lolans K, Queenan AM, Bush K, Sahud A, Quinn JP. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother 2005; 49:3538-40. (Pubitemid 41060613)
23. Health Protection Agency. Multi-resistant hospital bacteria linked to India and Pakistan. Health Protection Report 2009; 3. Available at: http://www.hpa.org.uk/hpr/archives/2009/news2609.htm. Accessed 17 February 2011.
24. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53:5046-54.
25. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10:597-602.
26. Deshpande P, Rodrigues C, Shetty A, Kapadia F, Hedge A, Soman R. New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: Treatment options with carbapenems compromised. J Assoc Physicians India 2010; 58:147-9.
27. Wiener-Well Y, Rudensky B, Yinnon AM, et al. Carriage rate of carbapenem-resistant Klebsiella pneumoniae in hospitalised patients during a national outbreak. J Hosp Infect 2010; 74:344-9.
28. Daikos GL, Petrikkos P, Psichogiou M, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009; 53:1868-73.
29. Endimiani A, Depasquale JM, Forero S, et al. Emergence of blaKPCcontaining Klebsiella pneumoniae in a long-term acute care hospital: A new challenge to our healthcare system. J Antimicrob Chemother 2009; 64:1102-10.
30. Perez F, Endimiani A, Ray AJ, et al. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: Impact of post-acute care facilities on dissemination. J Antimicrob Chemother 2010; 65:1807-18.
31. Urban C, Bradford PA, Tuckman M, et al. Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase betalactamases associated with long-term care facilities. Clin Infect Dis 2008; 46:e127-30. (Pubitemid 351706793)
32. Infectious Diseases Society of America. The 10x20 Initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 50:1081-3.
33. Schwaber MJ, Lev B, Israeli A, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011; 52:848-55.
34. Ben-David D, Maor Y, Keller N, et al. Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenemresistant Klebsiella pneumoniae infection. Infect Control Hosp Epidemiol 2010; 31:620-6.
35. Munoz-Price LS, De La Cuesta C, Adams S, et al. Successful eradication of a monoclonal strain of Klebsiella pneumoniae during a K. pneumoniae carbapenemase-producing K. pneumoniae outbreak in a surgical intensive care unit in Miami, Florida. Infect Control Hosp Epidemiol 2010; 31:1074-7.
36. Munoz-Price LS, Hayden MK, Lolans K, et al. Successful control of an outbreak of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae at a long-term acute care hospital. Infect Control Hosp Epidemiol 2010; 31:341-7.
37. Kochar S, Sheard T, Sharma R, et al. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2009; 30:447-52.
38. Centers for Disease Control and Prevention. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009; 58:256-60.
39. Anderson KF, Lonsway DR, Rasheed JK, et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 2007; 45:2723-5. (Pubitemid 47295515)
40. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. CLSI document M100-S18. Wayne, PA: CLSI, 2008.
41. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement (June 2010 update). CLSI document M100-S20-U Vol 30. Wayne, PA: Clinical and Laboratory Standards Institute, 2010.
42. Bilavsky E, Schwaber MJ, Carmeli Y. How to stem the tide of carbapenemase-producing Enterobacteriaceae?: Proactive versus reactive strategies. Curr Opin Infect Dis 2010; 23:327-31.
43. Calfee D, Jenkins SG. Use of active surveillance cultures to detect asymptomatic colonization with carbapenem-resistant Klebsiella pneumoniae in intensive care unit patients. Infect Control Hosp Epidemiol 2008; 29:966-8.
44. Buehlmann M, Fankhauser H, Laffer R, Bregenzer T, Widmer AF. The inguinal skin: An important site of colonization with extendedspectrum beta-lactamase-producing Enterobacteriaceae. Infect Control Hosp Epidemiol 2010; 31:427-8.
45. Zuckerman T, Benyamini N, Sprecher H, et al. SCT in patients with carbapenem resistant Klebsiella pneumoniae: A single center experience with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant 2010. first published online 8 November, 2010; doi:10.1038/ bmt.2010.279.
46. Siegel JD, Rhinehart E, Jackson M, Chiarello L, and Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007; 35:S165-93. (Pubitemid 350225593)
47. Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53:1983-6.
48. Gould CV, Umscheid CA, Agarwal RK, Kuntz G, Pegues, DA, and Healthcare Infection Control Practices Advisory Committee Guideline for prevention of catheter-associated urinary tract infections 2009. Infect Control Hosp Epidemiol 2010; 31:319-26.